2026 American Academy of Neurology Abstract Website

Objective:

This study retrospectively evaluates the clinical outcomes of MG patients treated with traditional versus novel therapies.

Background:

Myasthenia gravis (MG) is a neurological autoimmune disorder affecting neuromuscular transmission. The advent of novel therapies such as complement inhibitors and FcRn antagonists, has provided additional therapeutic potentials.

Design/Methods:

A retrospective chart review was performed on MG patients at a single tertiary center. Patient demographics characteristics were collected. Traditional Therapy Group (T) patients received acetylcholinesterase inhibitors, corticosteroids, or immunosuppressants, while Novel Therapy Group (N), had biologics such as Eculizumab (Soliris), Ravulizumab (Ultomiris), Zilucoplan, or Efgartigimod (Vyvgart). Clinical parameters, including MG-ADL score changes, rescue therapy requirements (IVIG/PLEX), ICU admissions, and MG related hospitalizations, were analyzed.

Results:

A total of 23 patients were included (15 in T group and 8 in N group). The average age of patients: 61.8 (±21.48) (T) vs 59.75 (±20.40) (N) years (p=0.82), comparable sex distribution (p=0.30). The age of disease onset were: 49.75 (±25.41) (T) and 53.25 (±21.63) (N) years (p=0.75), while comparable median disease duration (p=0.21). 4/15 (T) and 1/8 (N) patients were ocular MG subtype (p=0.62). No difference regarding MG specific antibodies (p=0.64) or thymectomy (p=0.67) or MG related crisis (p=0.071). N group had more MG-ADL score improvement: 4.75 (±6.52) vs 0.31(±1.80) points (p=0.0162).

Conclusions:

Our study suggests that novel therapies may provide better symptom control but remain limited by cost and insurance barriers. Larger studies are needed to evaluate long-term efficacy, safety and cost-effectiveness.